Verastem Inc (USD)
VSTM
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range2.14 | 2.31
52-Wk Range- | -
Last Close2.19
Mkt Cap (m)371.81
Dividend yield-
ISINUS92337C1045
Volume5,112,418.00
Exchange VenueNAS

Company Profile

Verastem Inc is a biopharmaceutical company engaged in discovering and developing drugs to improve outcomes for patients with cancer. Its product candidates include duvelisib and defactinib.

Key Information
Price/Earning-
Price/Book2.87
Price/Sales3.11
P/CF-
Rev Growth (3 year avg)-
EPS Growth (3 year avg)-
Operating Margin % -758.14
Net Margin %-854.77
Return on Equity-226.98
Debt/Equity14.99

Documents

Prospectus
en 27/04/2020
Annual Report
en 31/12/2019

Please refer to the below issuer website for further documents.

https://www.verastem.com

Financials

Income Statement
USD201420152016201720182019
Revenue (m)0.000.000.000.0026.7217.46
Operating Income (m)-53.61-58.20-37.00-67.80-94.78-132.34
Net Income (m)-53.37-57.87-36.44-67.80-72.43-149.21
Basic EPS-2.07-1.61-0.99-1.76-1.12-2.00
Avg. Diluted Shares Outstanding (m)25.8035.9336.9938.4269.3274.58
Balance Sheet
USD201420152016201720182019
Current Assets (m)95.32110.8481.3087.79253.2684.96
Non Current Assets (m)3.332.252.332.0023.9860.09
Total Assets (m)98.65113.0983.6389.79277.24145.05
Current Liabilities (m)9.2010.1110.9917.1337.0829.89
Total Liabilities (m)------
Total Equity (m)88.77102.4772.3057.68124.307.17
Cash Flows
USD201420152016201720182019
Operating Cash Flows (m)-36.90-45.56-29.48-57.31-74.52-138.52
Capital Expenditure (m)-2.43-0.21-0.04--23.51-0.01
Figures are quoted in USD unless stated otherwise
-
No change
$
2.19
Last Price